Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began to spread in late 2019, gradually depleting susceptible populations and causing the incidence of new infections to decline over time. Variation in individual susceptibility or exposure to infection exacerbated this effect. Individuals who were more susceptible or more exposed tended to be infected earlier, depleting the susceptible subpopulation of those who were at higher risk of infection. This selective depletion of susceptibles intensified the deceleration in incidence irrespectively of vaccination programmes. In a theoretical scenario of acquired immunity being long-lasting, susceptible numbers would eventually become low enough to prevent epidemic growth or, in other words, the herd immunity threshold (HIT) would be naturally reached. Early in the coronavirus disease (COVID-19) pandemic, simple calculations, relying on homogeneity assumptions, suggested that herd immunity would require 60-80% of the population to become immune. Here we build, into the underlying models, individual variation in susceptibility or in exposure to infection and demonstrate how that lowers the HIT. Based on data from a variety of sources and early parameter estimates these basic models suggest the HIT associated with natural infection to be in the order of 10-30% for SARS-CoV-2. We discuss how a structure accounting for unobserved selectable variation can be a core feature of infectious disease modelling embedded in model development as reality evolves and complexity is incremented. The goal is to enhance accuracy and enable trade-offs to be adequately addressed in the design of optimal policies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript are publicly available.
